Clinical evaluation of the SD Biosensor SARS-CoV-2 saliva antigen rapid test with symptomatic and asymptomatic, non-hospitalized patients

Zsofia Igloi1 *, Jans Velzing1, Robin Huisman1, Corine Geurtsvankessel1, Anoushka Comvalius1, Jeroen IJpelaar1, Janko van Beek1, Roel Ensing2, Timo Boelsums2, Marion Koopmans1, Richard Molenkamp1

1 Department of Viroscience, Erasmus Medical Centre, Rotterdam, The Netherlands, 2 Public Health Service Rotterdam-Rijnmond, Rotterdam, The Netherlands

* z.igloi@erasusmc.nl

Abstract

Background
Performance of the SD Biosensor saliva antigen rapid test was evaluated at a large designated testing site in non-hospitalized patients, with or without symptoms.

Method
All eligible people over 18 years of age presenting for a booked appointment at the designated SARS-CoV-2 testing site were approached for inclusion and enrolled following verbal informed consent. One nasopharyngeal swab was taken to carry out the default antigen rapid test from which the results were reported back to the patient and one saliva sample was self-taken according to verbal instruction on site. This was used for the saliva antigen rapid test, the RT-PCR and for virus culture. Sensitivity of the saliva antigen rapid test was analyzed in two ways: i, compared to saliva RT-PCR; and ii, compared to virus culture of the saliva samples. Study participants were also asked to fill in a short questionnaire stating age, sex, date of symptom onset. Recommended time of ≥30 mins since last meal, drink or cigarette if applicable was also recorded. The study was carried out in February-March 2021 for 4 weeks.

Results
We could include 789 people with complete records and results. Compared to saliva RT-PCR, overall sensitivity and specificity of the saliva antigen rapid test was 66.1% and 99.6% which increased to 88.6% with Ct ≤30 cutoff. Analysis by days post onset did not result in higher sensitivities because the large majority of people were in the very early phase of disease ie <3 days post onset. When breaking down the data for symptomatic and asymptomatic individuals, sensitivity ranged from 69.2% to 50% respectively, however the total
number of RT-PCR positive asymptomatic participants was very low (n = 5). Importantly, almost all culture positive samples were detected by the rapid test.

Conclusion

Overall, the potential benefits of saliva antigen rapid test, could outweigh the lower sensitivity compared to nasopharyngeal antigen rapid test in a comprehensive testing strategy, especially for home/self-testing and in vulnerable populations like elderly, disabled or children where in intrusive testing is either not possible or causes unnecessary stress.

Introduction

In spite of having multiple vaccines available [1], the COVID-19 pandemic is far from over and testing remains an essential pillar of the pandemic response. In high income countries, by now sufficient diagnostic capacities have been established however access to testing can be hindered by remote locations, lack of information, financial obstacles etc. Besides access, willingness is another factor which can be increased by simple, comfortable and non-invasive testing options. To increase access and testing rates, self/home testing approaches are explored and being implemented worldwide. However there is considerable debate on the drawbacks mostly from the disease surveillance and reliability of the results point of view [2]. This is because the multiple components which cannot be controlled over time when a non-trained professional carries out a test. The first step to make self/home testing an acceptable option is the availability of good reliable tests which are CE marked and fully evaluated for this specific application; these are still scarcely available [3]. Furthermore currently besides a few [4–6], most antigen rapid detection tests (RDTs) have only been validated using nasopharyngeal swabs which arguably can best be executed by trained health-care professionals and are less suited for self-testing. Suitability of saliva/oral fluid has been explored as a sample type both for molecular and serological test and found both higher and lower sensitivity for saliva samples compared with nasopharyngeal swabs. However, meta-analyses of such studies suggest an overall similar or non-statistically significant lower sensitivity associated with the use of saliva samples [7]. Taking patient comfort and ease of sampling in account saliva is definitely well suited also for self-sampling.

Because of the above mentioned reasons, we evaluated the clinical performance of a RDT utilizing saliva as sample amongst both symptomatic and asymptomatic general population presenting at testing locations. In order to have reliable data of the performance, samples were collected and tested by trained professionals. We have found acceptable [8] performance among symptomatic individuals who were in the early onset ie <7 days of disease. Results from this study can encourage further evaluation of RDTs using saliva thereby laying down the road towards inclusion saliva RDT in self-testing approaches.

Materials and methods

Testing site, testing procedures, population and patient recruitment

The study was carried out at an XL testing location in Rotterdam—Rijnmond (Rotterdam is the second largest city in the Netherlands) which is by appointment only. Persons with any respiratory symptoms, or persons that have been contacts of confirmed cases regardless of symptoms are eligible for a free of charge SARS-CoV-2 test. Vulnerable persons (ie elderly or chronic
condition) and priority groups (ie teachers, healthcare workers) are tested by reverse transcriptase polymerase chain reaction (RT-PCR), everyone else is tested by the SARS-CoV-2 Rapid Antigen Test (Distributed by Roche (SD Biosensor)) using a nasopharyngeal (NP) swab. In this study persons eligible for a rapid antigen test were enrolled. The SARS-CoV-2 Rapid Antigen Test-Standard Q COVID-19 Ag Saliva- Research use only (Lot number QCO9021001; expiry date 04-01-2023) was provided by SD Biosensor (http://www.sdbiosensor.com/xe/) but at time of writing this rapid antigen test was not available on the market.

At the entrance of the testing site all eligible people over 18 years of age were approached for inclusion and enrolled following verbal informed consent. Study participants were also asked to fill in a questionnaire stating age, sex, date of symptom onset. Recommended time of ≥30mins since last meal, drink or cigarette if applicable was also recorded. The study was carried out for 4 weeks (10 February-19 March) to reach an ideally total of 1000 inclusions. Study was terminated just prior to reaching the target at 816 inclusions for logistic reasons. From this, 789 had a PCR result due to a laboratory logistic problems.

**Specimen collection, testing and culture procedures**

Saliva was collected based on instructions of use by the test provider (nasal discharge and posterior pharyngeal spitting drooled into collection device) using the Zeesan Saliva RNA collection kit without preservation medium (http://www.zeesandx.com/coronavirus/1075.html). All saliva samples were tested for SARS-CoV-2 RNA using the cobas® SARS-CoV-2 RT-PCR test on the COBAS6800 (Roche diagnostics). Genome copies/ml were calculated based on an in house established standard curve. All RT-PCR positive saliva samples were inoculated onto Vero cells following dilution with universal transport media (VTM) (HiViral; HiMedia Laboratories PVT, Ltd., https://www.himedialabs.com) to 6ml volume, filtration with 45μm bacterial filter and mixing with FBS: 1080ul saliva+VTM with 720ul FBS prior to freezing at -80°C for a maximum of two weeks. Samples were cultured for a maximum of 14 days or until cytopathic effect (CPE) was visible. The presence of SARS-CoV-2 was confirmed by immunofluorescence, using a rabbit polyclonal antibody targeting SARS CoV-2 nucleocapsid protein (Sino Biological Inc.).

**Data analysis**

Data from the RDTs, RT-PCR, virus culture and clinical questionnaire were merged using Microsoft Access (http://www.microsoft.com), and data analysis was performed using Microsoft excel and R software version 4.0.2 (https://www.r-project.org). Sensitivity and specificity of RDTs were calculated in relation to the saliva RT-PCR and virus culture results. As a comparator sensitivity of the nasopharyngeal RDT was also calculated however only to saliva RT-PCR results as no PCR could be carried out on nasopharyngeal samples. Negative and positive predictive values (NPV and PPV) were calculated using percentage PCR positivity figures as a good proxy for disease prevalence. Clopper-Pearson analysis was used to determine confidence intervals of proportions. Two sample t-test was used to define significance of difference between means.

**Ethical clearance**

The medical research ethics committee (MREC) of Erasmus Medical center decided the study was not subject to the Medical Research Involving Human Subjects Act (WMO) and did not require full review by an accredited MREC (protocol number MEC-2021-0083).
**Results**

In total 789 complete dataset were available for analysis. Results of both the saliva and the nasopharyngeal RDT and the virus culture was compared to RT-PCR results and categorized by RT-PCR Ct values as an indicator for viral load and detection limit, Table 1. Participants had a median age of 37 years, an equal proportion of males and female (male, 50.6%) and almost a quarter were smokers. Most people presenting for testing had symptoms (70.5%, 556/789) with recent onset of disease (median 2 days post onset). Of the symptomatic people who could provide the exact date of onset (545/556) vast majority was in the very early phase of disease (77.5% < 3days) which is also seen in the proportion of low Ct values amongst the study population (70% Ct ≤ 30). Of all participants, 7.9% tested positive by RT-PCR what was just below the current percentage positivity nationally (between 11.2%-8.6% during the course of

| Table 1. Characteristics of the study population. |
|-----------------------------------------------|
| **Total N (RT-PCR and RDT results)**          | 789 |
| **Age [median (min-max); N]**                  | 37 years (18–79 years) |
| **Sex [%M, (n/N)]**                            | 50.6% (399/789) |
| **Smoker [%Y, (n/N)]**                        | 20.8% (164/789) |
| **Symptoms present [%Y, (n/N)]**              | 70.5% (556/789) |
| **Days from symptom onset [median (min-max); N]** | 2 days (0–41); 545 |
| **Days 0–3 [n/N (%)]**                        | 431/545 (77.5%) |
| **Days 4–7 [n/N (%)]**                        | 91/545 (16.4%) |
| **Days 8+ [n/N (%)]**                         | 23/545 (4.1%) |
| **Positivity PCR SARS-2 E gene [%, (n/N)]**   | 7.9% (62/789) |
| **PCR Ct [median (min-max); N]**               | 27.6 (17.4–35.1); 62 |
| **Ct > 30 [n, (%)]**                          | 18.29% |
| **Ct ≤ 30 [n, (%)]**                          | 44.70.1% |
| **Ct > 25 [n, (%)]**                          | 25.40.3% |
| **Positivity NP RDT [%, (n/N)]**              | 6.6% (52/789) |
| **NP RDT samples with positive PCR result [n]** | 49 |
| **PCR Ct SARS-2 E gene [median (min-max); N]** | 26.6 (17.4–34.2); 49 |
| **Ct > 30 [n, (%)]**                          | 9.18.4% |
| **Ct ≤ 30 [n, (%)]**                          | 40.81.6% |
| **Ct > 25 [n, (%)]**                          | 22.44.9% |
| **Positivity saliva RDT [%, (n/N)]**          | 5.6% (44/789) |
| **Saliva RDT samples with positive PCR result [n]** | 41 |
| **PCR Ct [median (min-max); N]**               | 25.5 (17.4–34.2); 41 |
| **Ct > 30 [n, (%)]**                          | 2.4.9% |
| **Ct ≤ 30 [n, (%)]**                          | 39.95.1% |
| **Ct ≥ 25 [n, (%)]**                          | 25.60.9% |
| **Positivity saliva virus culture [%, (n/N)]** | 48.4% (30/62) |
| **Ct > 30 [n, (%)]**                          | 0.0% |
| **Ct ≤ 30 [n, (%)]**                          | 30.100% |
| **Ct > 25 [n, (%)]**                          | 21.70% |

Data of all included people in the study were analyzed by basic demographies, smoking status, date of disease onset, RT-PCR Ct values and virus culture result.

RT-PCR, reverse transcription PCR; RDT, antigen rapid detection test; Min-max, minimum and maximum; M, male; Y, yes; n/N, amount of total sample size NP, nasopharyngeal swab; Ct, cycle threshold; E gene, envelope gene;

https://doi.org/10.1371/journal.pone.0260894.t001
More positive samples were detected by the standard nasopharyngeal RDT than by saliva RDT (n = 52 vs. n = 44). All samples with Ct ≤ 30 could be cultured.

Sensitivity and specificity of the saliva RDT was analyzed in two ways: i, compared to saliva RT-PCR Table 2 and Fig 1; and ii, compared to virus culture Fig 1. Comparing to RT-PCR in saliva, overall sensitivity of the saliva RDT was 66.1%. When PCR Ct ≤ 30 (E gene copy/ml 2.17E+05) cutoff was used sensitivity increased to 88.6%. When breaking down the data for symptomatic and asymptomatic individuals, sensitivity ranged from 69.2% to 50% respectively, however the total number of RT-PCR positive asymptomatic participants was very low (n = 5). Analysis by days post onset did not result in higher sensitivities but this is due to the uneven representation of patients with various days post onset in the study population (majority <3 days). Specificity was comparable to previous findings using nasopharyngeal RDT compared to PCR (between 99.1% and 99.8%) [10].

As nasopharyngeal RDT was used for standard diagnostic in this population we have also calculated sensitivity and specificity of the nasopharyngeal RDT compared to RT-PCR in saliva as the only available material and compared the performance of the two RDTs. Overall sensitivity of saliva RDT was lower (66.1% vs. 79.0%). Similarly to saliva RDT, analysis by days post onset did not result in higher sensitivities but this is due to the uneven representation of patients with various days post onset in the study population (majority <3 days).

### Table 2. Sensitivity and specificity of both saliva and nasopharyngeal antigen RDT compared to RT-PCR.

|                              | Compared to saliva RT-PCR | Compared to saliva RT-PCR |
|------------------------------|---------------------------|---------------------------|
|                              | 0–3 days post onset | 0–7 days post onset | Overall | Symptomatic | Asymptomatic |
| **Saliva RDT**               |                        |                        |         |            |             |
| Sensitivity% (CI95%), n      | 68.5% (54.5–80.5) (37)   | 65.0% (51.6–76.9) (39)   | 66.1% (52.9–77.6) (41) | 69.2% (54.9–81.3) (36) | 50.0% (18.7–81.3) (5) |
| ≤ Ct 30, Sensitivity% (CI95%), n | 87.5% (73.2–95.8) (35) | 88.1% (74.4–96.0) (37) | 88.6% (75.4–96.2) (39) | 88.2% (72.6–96.7) (30) | 83.3% (35.9–99.6) (5) |
| Specificity% (CI95%), n      | 99.7% (98.8–99.9) (619) | 99.6% (98.8–99.9) (703) | 99.6% (98.8–99.9) (724) | 99.8% (98.9–99.9) (503) | 99.1% (96.8–99.9) (221) |
| NPV% (CI95%)                 | 96.7% (95.1–97.7) | 96.3% (94.8–97.3) | 96.4% (95.0–97.4) | 96.7% (95.2–97.8) | 94.8% (90.7–97.1) |
| PPV% (CI95%)                 | 95.9% (85.3–99.0) | 96.3% (94.8–97.3) | 94.6% (84.9–98.2) | 97.5% (84.3–99.7) | 86.0% (57.4–96.5) |
| **NP RDT**                   |                        |                        |         |            |             |
| Sensitivity% (CI95%), n      | 79.2% (65.0–89.5) (38) | 78.7% (66.3–88.1) (48) | 79.0% (66.8–88.3) (49) | 82.7% (69.7–91.8) (43) | 60.0% (26.2–87.9) (6) |
| ≤ Ct 30, Sensitivity% (CI95%), n | 90.0% (76.3–97.2) (36) | 90.5% (77.4–97.3) (38) | 90.9% (78.3–97.5) (40) | 91.2% (76.3–98.1) (31) | 83.3% (35.9–99.6) (5) |
| Specificity% (CI95%), n      | 99.5% (98.6–99.9) (618) | 99.6% (98.8–99.9) (703) | 99.6% (98.8–99.9) (724) | 99.6% (98.6–99.9) (502) | 99.6% (97.5–99.9) (222) |
| NPV% (CI95%)                 | 97.8% (96.2–98.7) | 97.7% (96.3–98.6) | 97.8% (96.4–98.6) | 98.1% (96.7–99.0) | 95.8% (91.4–98.0) |
| PPV% (CI95%)                 | 94.7% (85.2–98.3) | 95.3% (86.7–98.5) | 95.5% (87.1–98.5) | 95.8% (85.1–98.9) | 93.6% (66.1–99.1) |

Overall and stratified sensitivity and specificity with 95% confidence interval (CI95%) of the saliva and nasopharyngeal antigen RDT compared to RT PCR. Results were also analyzed by days post onset and symptom status. Negative and positive predictive values (NPV and PPV) were calculated using the mean 9.9% PCR positivity nationally as a proxy for prevalence [9] during the study period.

https://doi.org/10.1371/journal.pone.0260894.t002
symptom status or by days post onset separately a similar difference was seen (symptoms present 69.2% vs. 82.7; <3 days 68.5% vs 79.2%). However sensitivity was similar with Ct \(\leq 30\) cut-off (88.6% vs. 90.9%). Generally sensitivity of nasopharyngeal RDT was lower but specificity was equally high and comparable to our previous study [10].

All PCR positive saliva samples were inoculated onto cell culture and approximately half (48.4%, 30/62) resulted in a positive CPE (mean Ct 24.2 of positive samples) Fig 1. Almost all samples with a positive culture result were detected either by nasopharyngeal RDT (90%, 27/30) or by saliva RDT (97%, 29/30). Only one sample was not detected by both RDTs and demonstrated a relatively high Ct-value (Ct 29). Culture negative samples (51.6%, 32/62) had higher Ct values (mean Ct 30.2 (p = 0.001). Results of the two RDTs were partially in concordance as 10/32 were not detected by neither tests. The n = 9 culture negative samples which were not detected by the saliva RDT were in the high Ct value range (median Ct 31.5). However there were n = 13 RDT positive but culture negative samples ranging from low to high Ct.

Fig 1. Cycle thresholds and genome copies of RT-PCR positive samples in relation to days since symptom onset, saliva and nasopharyngeal RDT positivity, and culture outcomes of participation with both symptomatic and asymptomatic patient (n = 62). Data points shown on the left side of the dashed bar are from asymptomatic individuals. NP, nasopharyngeal swab; RDT, antigen rapid detection test; C\textsubscript{t}, cycle threshold; E gene, envelope gene; Neg, negative; Pos, positive; RT-PCR, reverse transcription PCR.

https://doi.org/10.1371/journal.pone.0260894.g001
Discussion

There is very limited data available on the performance of saliva based RDTs [11, 12] and those that are available show below optimal results. The published studies report sensitivities of 63% and 24% compared to nasopharyngeal or nasal swab utilizing RDTs. In our study we have found that people with high viral load (Ct\textless 30 cutoff) could be detected with a saliva antigen RDT with relatively high sensitivity (88.6%). Furthermore, the majority of presumed infectious individuals (based on cell culture positivity in saliva) could be detected (96.7%). However there is still much to learn about viral kinetics in saliva and how it compares in patients with various disease severity, to other respiratory samples and the role of SARS-CoV-2 specific antibodies in saliva.

Currently nasopharyngeal swab remain the gold standard method for both PCR and RDT with room for exploration for saliva as evidence is still mostly lacking to fully understand the usability and reliability at various time points during disease and in different populations over time [7]. In this study, nasopharyngeal RDT was used as default diagnostic method and also as an additional reference method for the saliva RDT and demonstrated lower sensitivity and comparable specificity to our previous evaluation [10]. Reasons for this difference can be the changing population and also the comparator which was saliva RT-PCR. Using saliva RDT, despite lower general sensitivity compared to both saliva RT-PCR and nasopharyngeal RDT, based on RT-PCR Ct/viral load values almost all presumed infectious individuals could be detected, however this result could not be compared to nasopharyngeal swab virus culture in the current study. Saliva is a complex material shown to have comparable or slightly lower viral load to nasopharyngeal sample [13], it also contains SARS-2 specific antibodies [14] and different viral kinetics compared to nasopharynx which might explain the lower performance in the tested population. Furthermore, we have evaluated this test on non-hospitalized patients and a study found correlation of more severe disease with higher viral load in saliva [15].

Although our study is limited in the suboptimal number of positive samples, it provides promise for further exploration of saliva based RDTs to be used also for self/home testing. We did not investigate acceptance of saliva vs other invasive sample types but one could argue that collection of saliva is easier to perform and causes minimal discomfort and some studies showed high acceptability [16]. Limited studies on usability of RDTs showed relatively high sensitivity and low false negativity related to self-testing and these studies used either nasal or nasopharyngeal samples [17]. However comprehensive studies are still mostly lacking. Risk of aerosol generation could be higher in oral fluid sampling depending on exact sample type involving forced coughing. This risk for home/self-testing does not present an issue however for testing sites proper mitigation steps and set-up need to be thought of.

Availability of easy to use, comfortable RDTs might also increase willingness to test. Multiple studies showed that ease of access ie by central location of testing site or positive experience by minimizing discomfort and rapid availability of results all increased willingness [2, 18, 19]. Increased testing also helps with prompt identification and isolation of cases thereby stopping the spread. However the reliability of the test result depends also on disease prevalence in the population when the test is taken. At the time of our study the mean disease prevalence was 30/100,000 with a mean % PCR positivity of 9.9% resulting in a positive predictive value of the saliva RDT of 94.6%. By the time of the writing of the manuscript the lowest and the highest prevalence ranged between 2.9 (2.3% PCR positivity) and 58.4/100.00 (20.1% PCR positivity). If we apply these scenarios for the test performance, this would translate into 79.1%-97.6% PPV. Given the good specificity of the test the even under high prevalence the NPV still remains over 90% (99.2%– 92.1%) but there will still be individuals who obtain false negative results. The impact on transmission of false negative results should be considered, as
individuals may demonstrate lower adherence to non-pharmaceutical measures believing that they tested negative. Furthermore with already high and still increasing vaccination rates continuous decline in prevalence could be expected and need to be taken into account for future testing policies.

Overall, the potential benefits of saliva RDT, could outweigh the lower sensitivity in a targeted and comprehensive testing strategy, especially for home/self-testing and in vulnerable populations like elderly, disabled or children where in intrusive testing is either not possible or causes unnecessary stress.

### Supporting information

**S1 File.** (xlsx)

### Acknowledgments

Testing was carried out at the Ahoy XL testing centre in Rotterdam, the Netherlands, where numerous people contributed to the success of this project. We would like to thank all study participants, employees of the GGD Rotterdam—Rijmond especially all laboratory coordinators, namely Jelena Pajic, Lars Kortenhorst, Niekeline Kimmel, Ono Bestman, Bert de Valk, Sylviana Anthony for participation, coordination and the laboratory workers who carried out the rapid antigen tests.

### Author Contributions

**Conceptualization:** Zsofia Igloi, Jans Velzing, Robin Huisman, Corine Geurtsvankessel, Roel Ensing, Timo Boelsums, Richard Molenkamp.

**Data curation:** Robin Huisman.

**Formal analysis:** Zsofia Igloi, Janko van Beek.

**Investigation:** Zsofia Igloi.

**Methodology:** Zsofia Igloi, Robin Huisman, Corine Geurtsvankessel, Anoushka Comvalius, Jeroen Ilpelaar, Richard Molenkamp.

**Supervision:** Zsofia Igloi, Jans Velzing, Richard Molenkamp.

**Writing – original draft:** Zsofia Igloi.

**Writing – review & editing:** Corine Geurtsvankessel, Anoushka Comvalius, Janko van Beek, Marion Koopmans, Richard Molenkamp.

### References

1. Organization WH. The COVID-19 candidate vaccine landscape and tracker. 2021.
2. ECDC. Considerations on the use of self-tests for COVID-19 in the EU/EEA. 2021.
3. Commission E. COVID-19 In Vitro Diagnostic Devices and Test Methods Database. 2021.
4. Andreas K. Lindner ON, Kausch Franka, Wintel Mia, Hommes Franziska, Gertler Maximilian, Krüger Lisa J., et al. Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected anterior nasal swab versus professional-collected nasopharyngeal swab. Eur Respir J. 2021;2021 Feb 25:2003961. https://doi.org/10.1183/13993003.03961-2020; PubMed Central PMCID: PMCID: PMC7736752. PMID: 33303544
5. Yuto Takeuchi YA, Kato Daisuke, Kuwahara Miwa, Muramatsu Shino, Ueda Atsuo, Notake Shigeyuki, et al. Diagnostic Performance and Characteristics of Anterior Nasal Collection for the SARS-CoV-2
6. Olga Nikolai CR, Tobian Frank, Junge Andrea, Corman Victor M., Jones Terry C., Gaeddert Mary, et al. Anterior nasal versus nasal mid-turbinate sampling for a SARS-CoV-2 antigen-detecting rapid test: does localization or professional collection matter? medRxiv 2021;2021.02.09.21251274. https://doi.org/10.1101/2021.02.09.21251274 PMID: 34445926

7. ECDC. Considerations for the use of saliva as sample material for COVID-19 testing. 2021.

8. (WHO) WHO. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. 2020. Epub 11 September 2020.

9. RIVM. Coronadashboard. 2021.

10. Igloi Z, Velz Jing J, van Beek J, van de Vijver D, Aron G, Ensing R, et al. Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands. Emerg Infect Dis. 2021; 27(5):1323–9. Epub 2021/03/17. https://doi.org/10.3201/eid2705.204688 PMID: 33724916; PubMed Central PMCID: PMC8084500.

11. Priya Kannian CL, Ravichandran Krittika, Jayaraman Bagavadar, Mahanath Pasuvaraj, Ashwini Veeraraghavan, Kumarasamy Nagalingeswaran, et al. Detection of SARS-CoV2 antigen in human saliva may be a reliable tool for large scale screening. medRxiv 2020;2020.12.17.20248437. https://doi.org/10.1101/2020.12.17.20248437.

12. Isao Yokota TS, Sugita Junichi, Iwasaki Sumio, Yasuda Naoki, Fujisawa Shinichi, et al. Performance of qualitative and quantitative antigen tests for SARS-CoV-2 in early symptomatic patients using saliva. medRxiv 2020;2020.11.06.20227363. https://doi.org/10.1101/2020.11.06.20227363.

13. Tsang NNY, So HC, Ng KY, Cowling BJ, Leung GM, Ip D KM. Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis. Lancet Infect Dis. 2021. Epub 2021/04/16. doi: S1473-3099(21)00146-8 [pii] https://doi.org/10.1016/S1473-3099(21)00146-8 PMID: 33857405; PubMed Central PMCID: PMC8041361 authors declare no competing interests.

14. Carlota Dobaño SA, Vidal Marta, Jiménez Alfons, Rubio Rocío, Santano Rebeca, Barrios Diana, et al. Multiplex Antibody Analysis of IgM, IgA and IgG to SARS-CoV-2 in Saliva and Serum from Infected Children and their Close Contacts. medRxiv 2021. https://doi.org/10.1101/2021.03.22.21254120.

15. Julio Silva CL, Sundaram Maria, Israelow Benjamin, Wong Patrick, Klein Jon, Tokuyama Maria, et al. Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality. medRxiv 2021;2021.01.04.21249236; https://doi.org/10.101102/2021.01.04.21249236 PMID: 33442706

16. Goggoldou P, Hodges-Mameletzis I, Purewal S, Karakoula A, Warr T, Self-Testing as an Invaluable Tool in Fighting the COVID-19 Pandemic. J Prim Care Commun. 2021; 12. doi: ArtN 21501327211047782 https://doi.org/10.1177/21501327211047782 PubMed PMID: WOS:000703780700001. PMID: 34583571

17. Stohr VFZ J. J.J.M., Goderski G., Meijer A., Nagel-Imming C. R.S., Kluytmans-van den Bergh M.F.Q., Pas S. D., et al. Self-testing for the detection of SARS-CoV-2 infection with rapid antigen tests. medRxiv 2021. https://doi.org/10.1101/2021.02.21.21252153

18. Wolfers MEG, Kok G, Mackenbach JP, de Zwart O. Correlates of STI testing among vocational school students in the Netherlands. Bmc Public Health. 2010; 10. doi: ArtN 725 https://doi.org/10.1186/1471-2458-10-725 PubMed PMID: WOS:000285594700002. PMID: 21106064

19. de Visser RO, O’Neill N. Identifying and understanding barriers to sexually transmissible infection testing among young people. Sex Health. 2013; 10(6):553–8. https://doi.org/10.1071/SH13034 PubMed PMID: WOS:000368061000012. PMID: 24160762